Stock comparison
Alvotech
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 65C | GMAB |
| Benjamin Graham | 51D | 64C | GMAB |
| Philip Fisher | 55C | 48D | ALVO |
| Peter Lynch | 78C | 25F | ALVO |
| Joel Greenblatt | 45D | 76B | GMAB |
| Charlie Munger | 52D | 68C | GMAB |
| Terry Smith | 43D | 71C | GMAB |
Side-by-side metrics
| Metric | ALVO | GMAB |
|---|---|---|
| Market cap | $1.04B | $16.5B |
| P/E (TTM) | 33.1x | 6.2x |
| EV/EBIT | 29.5x | 12.0x |
| ROIC (TTM) | 1.3% | 43.78% |
| Gross margin | 59.82% | 93.88% |
| Net margin | 4.76% | 18.23% |
| Revenue CAGR 5y | 99.83% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Revenue CAGR 5y99.83%vs -18.45%+118%
- Debt / Equity-vs 0.1x+101%
GMAB leads on
- ROIC (TTM)43.78%vs 1.3%+97%
- Market cap$16.5Bvs $1.04B+94%
- P/E (TTM)6.2xvs 33.1x+81%
- Net margin18.23%vs 4.76%+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.